Pharma Technology Focus is now published monthly and free for the iPad. Download our app to read the latest issue and browse our back issues for free.
Scientists in Scotland have discovered an anti-malarial compound that could eventually treat the disease and prevent its transmission with a dose that costs just $1. We look into this promising research and find out whether it could turn a new page for malaria treatment.
While the threat of antimicrobial resistance continues to grow, antibiotics innovation has stalled due to a lack investment. We ask what can be done to attract much-needed funds to this vital area of drug development. We also investigate why Parkinson’s trails continue to suffer from low success rates, and review research suggesting that statins could find a new application in improving cancer survival rates.
Moreover, we find out how London Mayor Boris Johnson aims to attract pharma business to the city with a £10bn ‘megafund’, and investigate what a British exit from the EU could mean for the country’s pharma companies and their European counterparts.
In this issue
Brexit: Be PreparedAs the UK’s EU membership referendum looms on the horizon, what could a British exit mean for UK pharma companies? Chris Lo asks why the industry should make its views clear before the debate kicks off.Read the article.
A Capital IdeaLondon Mayor Boris Johnson has proposed a £10bn ‘megafund’ to inject capital into the city’s life sciences sector and attract new drug developers. Abi Millar finds out more.Read the article.
Elephant in the RoomWhile the threat of antimicrobial resistance continues to grow, antibiotics innovation has stalled due to a lack investment. Chris Lo asks what can be done to attract much-needed funds to this vital area of drug development.Read the article.
The $1 CureScientists at the University of Dundee have discovered an anti-malarial compound that could eventually treat the disease and prevent its transmission with a $1 dose. Rod James finds out more about the promising research.Read the article.
Meeting in the MiddleClinical trials for Parkinson’s disease aren’t attracting enough patients, despite the urgent need for new medications. Elly Earls finds out more about the barriers to effective PD trials and the best ways to overcome them.Read the article.
Hidden PotentialStatins may play a vital role in preventing deaths from cancer, according to two recent observational studies. Abi Millar explores the findings and the potential for statin-based cancer therapies.Read the article.
Cometriq’s Rollercoaster RideAs Exelixis keeps exploring commercial opportunities for Cometriq, Melina Reisenberg, PhD, GlobalData analyst for oncology, takes a look at the drug’s recent progress.Read the article.
Next issue preview
As the US Drug Quality and Security Act, conceived to protect patients against contaminated and counterfeit products and signed into law in 2012, starts to come into effect, we review the requirements and ask how the changes will help secure the country’s pharmaceutical supply chain.
We also take a look at innovations in asthma therapies, find out why a new class of synthetic compounds called antimicrobial lipopeptides could represent a promising alternative to traditional antibiotics, and check in on efforts to develop new pain drugs that are resistant to abuse.
With the latest employment figures from the UK revealing stalled employment growth in the pharma sector, we ask recruiters how companies can attract and retain top talent in STEM roles. Plus, ProductLife Group tells us how companies can break down barriers between regulation and pharmacovigilance to improve process efficiencies.
Digital magazine FAQ
You can read Pharma Technology Focus for free on the iPad. Download our app from the App Store to read the latest issue and browse the back issues in our archive. Sign up for a free subscription in the app and never miss a new issue.
You can also continue to read the desktop version for free on our web viewer. (Browser compatibility: The web viewer works in the latest two version of Chrome, Firefox and Safari, as well as in Internet Explorer 9 and 10. Some features may not be compatible with older browser versions.)